Since the vast majority of HCL patients carry the BRAF p.V600E mutation the use of vemurafenib, a BRAF inhibitor, that shows an unusual specificity for the p.V600E mutation has been suggested in individual patients as early as 2012. This evidence concerns the gene BRAF and hairy cell leukemia.